April 19 (Bloomberg) -- Astellas Pharma Inc. said it won’t raise its $3.5 billion unsolicited bid for OSI Pharmaceuticals Inc. after the target company won approval for expanded use of its main drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.